Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration ...

Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

Easley's leadership has been pivotal in tackling complex cases ranging from white-collar crimes to drug trafficking.

BlueArc Biosciences has been a winner in all three phases so far of the LymeX Innovation Accelerator competition as it works ...

A few companies are in clinicals with novel approaches to heal an initial brain injury or minimize secondary damage. Slow progress may be more related to investors’ misperceptions of the topic than ...

Pepe Unchained ($PEPU) launched its Layer 2 Pepe Pump Pad, aiming to do for Ethereum what Pump.fun did for Solana, sending ...

The FDA has offered positive feedback on possible paths forward for accelerated or traditional approval of FLT201 using data from a single-arm study.

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week.

International collaborations, refined gene-editing protocols, and targeted immunologic maneuvers keep the cancer gene therapy ...

Horizon Kinetics have published their Q4 2024 Commentary. How’d we do? How’d the market do? What to expect now? Click here to ...